News
12-30-2009, 09:10 AM
Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers...
More... (http://mnt.to/f/3vt2)
More... (http://mnt.to/f/3vt2)